Art. -Nr.: HY-127103

FB23-2

29 Cited Publications

Kundenbewertung

Based on 29 publication(s) in Google Scholar

FB23-2 is a potent and selective inhibitor of mRNA N⁶-methyladenosine (m⁶A) demethylase FTO, with an IC₅₀ of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.55%
CAS. Nr.: 2243736-45-8
Formel: C₁₈H₁₅Cl₂N₃O₃
Molecular Weight:392.24

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

FB23-2 Chemical Structure

CAS. Nr.: 2243736-45-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 2.6 μM (FTO)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
MONO-MAC-6	IC₅₀	0.8 μM Compound: FB23-2	Antiproliferative activity against human MONO-MAC-6 cells Antiproliferative activity against human MONO-MAC-6 cells	[PMID: 32330741]
NB-4	IC₅₀	0.8 μM Compound: FB23-2	Antiproliferative activity against human NB-4 cells Antiproliferative activity against human NB-4 cells	[PMID: 32330741]
NB-4	IC₅₀	0.8 μM Compound: FB23-2	Antiproliferative activity against human NB4 cells measured after 72 hrs by celltiter96 aqueous non-radioactive cell proliferation assay Antiproliferative activity against human NB4 cells measured after 72 hrs by celltiter96 aqueous non-radioactive cell proliferation assay	[PMID: 37974948]

In Vitro

FB23-2 dramatically suppresses proliferation and promotes the differentiation/apoptosis of human AML cell line cells and primary blast AML cells^[1].
FB23 inhibits the proliferation of NB4 and MONOMAC6 cells, with IC₅₀ values of 0.8 μM and 1.5 μM^[1].
FB23-2 (20 μM; 72 hours) displays anti-proliferation effect via upregulating global m⁶A levels^[1].
FB23-2 (0.5-5 μM; 24-72 hours) significantly suppresses the proliferation of BM cells from these two models in a dose-dependent manner^[1].
FB23-2 exhibits FTO-dependent anti-proliferation activity and promotes myeloid differentiation and apoptosis^[1].
FB23-2 (1-20 μM; 72 hours) significantly increases the mRNA and protein levels of ASB2 and RARA in NB4 and MONOMAC6 cells^[1].
FB23-2 induces apoptosis (1-20 μM; 48-72 hours) and cell cycle arrest (5-20 μM; 24 hours) at G1 stage in AML cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

MA9 cells, FLT3ITD/NPM1 cells (mouse BM cells)
Concentration:

0.5 μM, 2 μM, 5 μM
Incubation Time:

24 hours, 48 hours, 72 hours
Result:

Suppressed the proliferation of BM cells.

RT-PCR^[1]

Cell Line:

NB4 cells, MONOMAC6 cells
Concentration:

1 μM, 5 μM , 20 μM
Incubation Time:

72 hours
Result:

Significantly increased ASB2 and RARA mRNA levels.

Apoptosis Analysis^[1]

Cell Line:

NB4 cells, MONOMAC6 cells
Concentration:

1 μM, 5 μM , 20 μM
Incubation Time:

48 hours (NB4 cells),72 hours (MONOMAC6 cells)
Result:

Induced apoptosis.

Cell Cycle Analysis^[1]

Cell Line:

MONOMAC6 cells
Concentration:

5 μM , 20 μM
Incubation Time:

24 hours
Result:

Induced cell cycle arrest at G1 stage.

In Vivo

FB23-2 (2 mg/kg; i.p.; daily; for 10 days) substantially suppresses leukemia progression and prolongs survival^[1].
FB23-2 exhibits elimination half-life (rat 6.7 h) and C_max (rat 2421.3 ng/mL) following intraperitoneal injection (rat 3 mg/kg)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NOD/LtSz-scid IL2RG-SGM3 (NSGS) mice, xeno-transplanted with MONOMAC6 AML cells^[1]
Dosage:

2 mg/kg
Administration:

Intraperitoneal injection, daily, for 10 days
Result:

Delayed the onset of full-blown leukemic symptoms and significantly prolonged survival by almost doubling the median survival.

Animal Model:

Sprague Dawley (SD) rats^[1]
Dosage:

3 mg/kg (Pharmacokinetic Analysis)
Administration:

Intraperitoneal injection
Result:

T_1/2 (6.7 hours), C_max (2421.3 ng/mL).

Chemical Information

CAS. Nr. 2243736-45-8
Appearance Solid
Molecular Weight 392.24
Formel C₁₈H₁₅Cl₂N₃O₃
Color White to light yellow
SMILES

O=C(NO)C1=CC=CC=C1NC2=C(Cl)C=C(C3=C(C)ON=C3C)C=C2Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (29)

All Cell Proliferation/Viability AssayHistological Imaging/StainingBio/Physico-chemical AssayWBCell Imaging/Staining

Sort by:

Journal Impact Factor

Cell

Fine-tuning of gene expression through the Mettl3-Mettl14-Dnmt1 axis controls ESC differentiation. [Abstract]

2025 Feb 20;188(4):998-1018.e26. PMID: 39826545
Mol Cancer

FTO-mediated DSP m6A demethylation promotes an aggressive subtype of growth hormone-secreting pituitary neuroendocrine tumors. [Abstract]

2024 Sep 20;23(1):205. PMID: 39304899

FB23-2 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Sep 20;23(1):205. [Abstract]

Bar plots showing the octreotide sensitivity change after combing with FB23-2 (4 μM, 48 h) treatment in GH3 cells and primary tumor cells.

FB23-2 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Sep 20;23(1):205. [Abstract]

Bar plots showing the growth hormone level changes following octreotide and FB23-2 (4 μM, 48 h) treatment in GH3 cells (left) and primary tumor cells (right).

FB23-2 purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Sep 20;23(1):205. [Abstract]

Bar plots showing the octreotide sensitivity (left) and growth hormone level (right) change after combining with FB23-2 (4 μM, 48 h) in organoids.
Nat Commun

FTO deficiency in older livers exacerbates ferroptosis during ischaemia/reperfusion injury by upregulating ACSL4 and TFRC. [Abstract]

2024 Jun 4;15(1):4760. PMID: 38834654

FB23-2 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 4;15(1):4760. [Abstract]

Representative images and relative quantification/Suzuki score of HE staining (magnification, × 100), TUNEL staining (magnification, × 200), DHE staining (magnification, × 100) and C11 BODIPY staining (magnification, × 200) in older liver tissues with FB23-2 (20 mg/kg, intraperitoneally administered 2 h prior to ischaemia).

FB23-2 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 4;15(1):4760. [Abstract]

FB23-2 (20 mg/kg, intraperitoneally administered 2 h prior to ischaemia). Western blotting showed changes in the expression of key factors related to ferroptosis.

FB23-2 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jun 4;15(1):4760. [Abstract]

Representative images and relative quantification of Calcein-AM/PI double staining (magnification, × 100), DHE staining (magnification, × 200) and C11 BODIPY staining (magnification, × 200) to evaluate the effect of FB23-2 (20 mg/kg, intraperitoneally administered 2 h prior to ischaemia) on primary hepatocytes during H/R, one-way ANOVA followed by multiple comparisons.
J Exp Clin Cancer Res

m6A eraser FTO impairs gemcitabine resistance in pancreatic cancer through influencing NEDD4 mRNA stability by regulating the PTEN/PI3K/AKT pathway. [Abstract]

2023 Aug 22;42(1):217. PMID: 37605223
Adv Sci (Weinh)

m6A-Modified circTET2 Interacting with HNRNPC Regulates Fatty Acid Oxidation to Promote the Proliferation of Chronic Lymphocytic Leukemia. [Abstract]

2023 Dec;10(34):e2304895. PMID: 37821382
Int J Biol Sci

FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability. [Abstract]

2022 Oct 3;18(15):5943-5962. PMID: 36263177
Phytomedicine

Astragaloside IV inhibits retinal pigment epithelial cell senescence and reduces IL-1β mRNA stability by targeting FTO-mediated m6A methylation. [Abstract]

2025 Mar:138:156408. PMID: 39848020
J Hazard Mater

HFPO-TA inhibits testosterone synthesis by triggering FTO-mediated m6A modification to drive NCOA4-associated ferroptosis. [Abstract]

2026 Jun 16:514:142733. PMID: 42314315
J Hazard Mater

Extractable organic matter from PM2.5 inhibits cardiomyocyte differentiation via AHR-mediated m6A RNA methylation. [Abstract]

2025 Mar 15:486:137110. PMID: 39778483
J Hazard Mater

N6-methyladenosine promotes aberrant redox homeostasis required for arsenic carcinogenesis by controlling the adaptation of key antioxidant enzymes. [Abstract]

2024 Mar 5:465:133329. PMID: 38142659
J Hazard Mater

Cobalt induces neurodegeneration through FTO-triggered autophagy impairment by targeting TSC1 in an m6A-YTHDF2-dependent manner. [Abstract]

2023 Jul 5:453:131354. PMID: 37054644
J Hazard Mater

N6-methyladenosine plays a dual role in arsenic carcinogenesis by temporal-specific control of core target AKT1. [Abstract]

2023 Mar 5:445:130468. PMID: 36444808
Free Radic Biol Med

FTO inhibition represses B-cell acute lymphoblastic leukemia progression by inducing nucleolar stress and mitochondrial dysfunction. [Abstract]

2025 Oct:238:507-521. PMID: 40623539
EMBO Mol Med

Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy. [Abstract]

2024 Feb;16(2):294-318. PMID: 38297099
Cell Rep

Calcium influx drives m6A-dependent RUNX1T1 splicing to promote adipogenic commitment. [Abstract]

2026 May 28;45(6):117471. PMID: 42213774
Cell Rep

m6A modification inhibits miRNAs' intracellular function, favoring their extracellular export for intercellular communication. [Abstract]

2024 Jun 14;43(6):114369. PMID: 38878288
J Ethnopharmacol

Qiteng Xiaozhuo Granules improve chronic glomerulonephritis through promoting glomerular mesangial cell autophagy via FTO-mediated SLC7A5 m6A modification. [Abstract]

2026 Feb 28:357:120948. PMID: 41308711
BMC Biol

GnRH-driven FTO-mediated RNA m6A modification promotes gonadotropin synthesis and secretion. [Abstract]

2024 May 3;22(1):104. PMID: 38702712
Sci Rep

m6A demethylase FTO promotes the progression of abdominal aortic aneurysm through PDK4-mediated apoptosis. [Abstract]

2026 Apr 18;16(1):17992. PMID: 42000779
Cell Signal

The m6A RNA demethylase FTO promotes radioresistance and stemness maintenance of glioma stem cells. [Abstract]

2025 Aug:132:111782. PMID: 40185350
Eur J Orthod

Fat mass and obesity-associated protein (FTO) affects midpalatal suture bone remodeling during rapid maxillary expansion. [Abstract]

2024 Apr 1;46(2):cjae009. PMID: 38376496
J Cell Sci

A C-terminal cytoplasmic retention motif and nuclear localization signal regulates nuclear import of TP53INP2. [Abstract]

2025 Dec 15;138(24):jcs264267. PMID: 41368677
Mol Brain

Epitranscriptomic profiling of N6-methyladenosine-related RNA methylation in rat cerebral cortex following traumatic brain injury. [Abstract]

2020 Jan 28;13(1):11. PMID: 31992337
Mol Carcinog

miR-150-5p Regulates Merkel Cell Carcinoma Progression by Targeting FTO That Stabilizes CTNNB1 via m6A Modification. [Abstract]

2025 Aug 22. PMID: 40844235
bioRxiv

2026 Mar 13.
SSRN

2025 Nov 6.
bioRxiv

FTO depletion does not alter m6A stoichiometry in AML mRNA: a reassessment using direct RNA nanopore sequencing. [Abstract]

2025 Oct 23:2025.10.22.681652. PMID: 41279954
Research Square Preprint

2024 Apr 8.
bioRxiv

2023 May 19.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (63.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5495 mL

12.7473 mL

25.4946 mL

5 mM

0.5099 mL

2.5495 mL

5.0989 mL

10 mM

0.2549 mL

1.2747 mL

2.5495 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.30 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (25.49 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5495 mL	12.7473 mL	25.4946 mL	63.7365 mL
	5 mM	0.5099 mL	2.5495 mL	5.0989 mL	12.7473 mL
	10 mM	0.2549 mL	1.2747 mL	2.5495 mL	6.3736 mL
	15 mM	0.1700 mL	0.8498 mL	1.6996 mL	4.2491 mL
	20 mM	0.1275 mL	0.6374 mL	1.2747 mL	3.1868 mL
	25 mM	0.1020 mL	0.5099 mL	1.0198 mL	2.5495 mL
	30 mM	0.0850 mL	0.4249 mL	0.8498 mL	2.1245 mL
	40 mM	0.0637 mL	0.3187 mL	0.6374 mL	1.5934 mL
	50 mM	0.0510 mL	0.2549 mL	0.5099 mL	1.2747 mL
	60 mM	0.0425 mL	0.2125 mL	0.4249 mL	1.0623 mL

Keywords

FB23-2

29 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

FB23-2

Apoptosis Compound Library

Anti-Cancer Compound Library

Anti-Blood Cancer Compound Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) FB23-2

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

FB23-2

Apoptosis Compound Library

Anti-Cancer Compound Library

Anti-Blood Cancer Compound Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) FB23-2

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

FB23-2 Related Classifications

HY-127103 Related Classifications